Brennan P, Bankhead C, Silman A, Symmons D
Arthritis and Rheumatism Council Epidemiology Research Unit, University of Manchester Medical School, England, UK.
Semin Arthritis Rheum. 1997 Jun;26(6):817-23. doi: 10.1016/s0049-0172(97)80025-x.
The possibility that oral contraceptives offer a protective effect against the development of rheumatoid arthritis is still contentious. Of the 17 studies investigating this association, 11 have found a protective effect, and 6 have not. These differences are probably attributable to either selection or information biases in a subset of studies, although the exact reason is unknown. To overcome the methodological problems inherent in the design of previous studies, we have conducted a population-based case-control study.
Women who were incident cases of inflammatory polyarthritis, defined as swelling of at least two joint areas lasting at least 4 weeks, were recruited directly from primary care and compared with age-matched women from the same population.
Cases and controls reported a similar level of "ever use" of oral contraceptives, adjusted odds ratio = 0.88 (95% confidence interval, 0.47, 1.64). The cases were, however, less likely to report using oral contraceptives at the time of onset, adjusted odds ratio = 0.22 (95% confidence interval, 0.06, 0.85). Similar results were observed for cases who satisfied the criteria for rheumatoid arthritis and cases who did not.
These results indicate that only current oral contraceptive use protects against the development of inflammatory polyarthritis.
口服避孕药对类风湿关节炎的发生具有保护作用这一可能性仍存在争议。在17项调查此关联的研究中,11项发现有保护作用,6项则未发现。这些差异可能归因于部分研究中存在的选择偏倚或信息偏倚,尽管确切原因尚不清楚。为克服既往研究设计中固有的方法学问题,我们开展了一项基于人群的病例对照研究。
从初级保健机构直接招募炎症性多关节炎的新发病例女性,定义为至少两个关节区域肿胀持续至少4周,并与来自同一人群的年龄匹配女性进行比较。
病例组和对照组报告的口服避孕药“曾经使用”水平相似,调整后的优势比=0.88(95%置信区间,0.47,1.64)。然而,病例组在发病时报告使用口服避孕药的可能性较小,调整后的优势比=0.22(95%置信区间,0.06,0.85)。对于符合类风湿关节炎标准的病例和不符合标准的病例,观察到了类似的结果。
这些结果表明,仅当前使用口服避孕药可预防炎症性多关节炎的发生。